Meta description: A regulatory update on the HeartLogic Diagnostic trial that tests threshold changes to improve guideline directed medical therapy in chronic heart failure with low ejection fraction.
On February 19 2026 a ClinicalTrials.gov record outlines a study evaluating the HeartLogic Diagnostic Tool as a path to optimize guideline directed medical therapy in patients with chronic heart failure and chronically low ejection fraction. The trial compares two device settings the HeartLogic Diagnostic Tool threshold change and the unchanged threshold. The sponsors listed are Robert Pickett Boston Scientific Corporation and Ascension Health and the study is not yet recruiting. The disclosure frames a device based approach to supporting medical decision making in a patient group at elevated risk for disease progression.
What changed in the HeartLogic evaluation?
The study centers on the HeartLogic Diagnostic Tool and its threshold settings. It compares a threshold change against the unchanged threshold in patients who have chronic heart failure and low ejection fraction. The aim is to understand whether adjusting device delivered alerts or signals can support optimization of guideline directed medical therapy. The description does not report results but notes the comparison of two approaches within a single trial frame. The emphasis is on how device based monitoring may influence clinical decision making in a high risk population. The statements come from a ClinicalTrials.gov record that lists sponsors Boston Scientific and Ascension Health and identifies the trial as not yet recruiting.
What is HeartLogic Diagnostic Tool?
The HeartLogic Diagnostic Tool is described in the trial as a device based diagnostic capability used to monitor signals available to the trial participants. The content is limited to what is in the record; it does not describe performance metrics or safety data in this release.
What is meant by threshold change versus unchanged threshold?
The trial defines two settings for the HeartLogic tool the threshold change arm and the unchanged threshold arm. The comparison seeks to reveal how threshold adjustments may affect the management of therapy as guided by established clinical pathways. The claim here is about study design not results and requires future data to assess effect on patient care.
How is the trial structured?
The protocol lists two device related arms the HeartLogic Diagnostic Tool Threshold Change and the HeartLogic Diagnostic Tool Unchanged Threshold. The text does not specify randomization or blinding. Sponsors include Boston Scientific and Ascension Health with Robert Pickett as listed contact. The trial is described as not yet recruiting at this time. The setup aligns with device oriented methods to evaluate potential impact on therapy optimization in chronic heart failure with low ejection fraction.
What are the study arms
The two arms involve a threshold change and an unchanged threshold for the HeartLogic Diagnostic Tool. Details on allocation and endpoints are not provided in the record.
Is randomization described
The available text does not state whether randomization is used. The description focuses on arms rather than trial design features.
Who should watch this study and why?
Clinicians who manage chronic heart failure and patients with low ejection fraction will be watching this trial. Device makers and health systems may use findings to shape integration of HeartLogic in care pathways. Regulators and payers may consider how threshold based alerts influence treatment decisions. Sponsors Boston Scientific and Ascension Health include both industry and health system partners. The record notes the not yet recruiting status.
Who is the clinical audience
Cardiologists heart failure specialists and advanced practice providers are primary stakeholders for GDMT decisions in this population.
What about industry and regulators
Device developers and hospital networks may monitor this trial for insights into device threshold workups and method implications. Regulators may await data on safety and performance before broad usage changes.
What is the regulatory context for threshold changes?
The entry aligns with a regulatory style that emphasizes intent purpose performance and safety as described in MDR Annex XIV. The statement notes that manufacturer claims are presented as such and not as clinical outcomes. The trial is described in the source as not yet recruiting and involves a well known medical device company. Readers should not infer approval status from this record.
How does MDR context apply to this trial
The MDR framework governs device changes including threshold settings. The record signals an evaluation not a finalized approval or labeling change at this stage.
What safety considerations apply?
Safety considerations focus on monitoring and ongoing risk assessment inherent to device based monitoring. The not yet recruiting status means no results are available yet. Stakeholders should evaluate how new threshold settings may affect the balance of benefit and risk in the heart failure population. The text does not report safety outcomes.
What monitoring plans are described
The source text mentions device threshold changes but does not disclose specific monitoring plans or safety endpoints. Readers should watch for updates from the sponsor or ClinicalTrials.gov.
- 1. What is HeartLogic Diagnostic Tool The trial mentions it as a device based diagnostic tool used in evaluating therapy optimization.
- 2. What is the purpose of the study To evaluate threshold change versus unchanged threshold as part of optimizing guideline directed medical therapy in chronic heart failure with low EF.
- 3. Who funds the study Sponsors include Boston Scientific Corporation Ascension Health and Robert Pickett.
- 4. Where can I find more information The ClinicalTrials.gov record is the source for details including recruitment status and study design.
Conclusion
In summary the trial outlines a comparison of HeartLogic threshold settings and aims to inform future guideline directed medical therapy optimization in patients with chronic heart failure and low ejection fraction. Stakeholders should monitor updates from ClinicalTrials.gov for recruitment status results and potential regulatory implications.
Disclaimer: This information is intended for professionals and is not legal advice. Consult applicable regulatory guidance for specifics.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07412626?term=medical+device